Abstract Neonates, particularly preterm infants, are a susceptible population to respiratory viral infections. Currently, aside from influenza, there are no antiviral medications specifically approved for the treatment of respiratory viral infections in neonates; therefore, prevention of these viral infections is particularly crucial for neonates. The Neonatal Health Care Committee of Chinese Maternal and Child Health Association, based on domestic and international clinical evidence and combined with clinical practice experience, and after thorough discussion by relevant experts, has developed eight expert recommendations. These include preventive strategies against influenza virus, respiratory syncytial virus, and severe acute respiratory syndrome coronavirus 2 infections, intended for reference in clinical practice.
Neonatal Health Care Committee of Chinese Maternal and Child Health Association. Expert recommendations for the prevention of common respiratory viral infections in neonates[J]. CJCP, 2024, 26(8): 789-794.
Neonatal Health Care Committee of Chinese Maternal and Child Health Association. Expert recommendations for the prevention of common respiratory viral infections in neonates[J]. CJCP, 2024, 26(8): 789-794.
2 Kimberlin DW, Barnett ED, Lynfield R, et al. Human Papillomaviruses[M]//Kimberlin DW, Barnett ED, Lynfield R, et al. Red Book (2021): Report of the Committee on Infectious Diseases. Itasca: American Academy of Pediatrics, 2021: 447.
Ip DKM, Lau LLH, Chan KH, et al. The dynamic relationship between clinical symptomatology and viral shedding in naturally acquired seasonal and pandemic influenza virus infections[J]. Clin Infect Dis, 2016, 62(4): 431-437. PMID: 26518469. PMCID: PMC4725380. DOI: 10.1093/cid/civ909.
4 Centers for Disease Control and Prevention. Influenza antiviral medications: summary for clinicians[C]. [2021-08-18]. https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm.
Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2022-2023[J]. Pediatrics, 2022, 150(4): e2022059274. PMID: 36065749. DOI: 10.1542/peds.2022-059274.
Bianchi FP, Stefanizzi P, Cuscianna E, et al. Effectiveness of on-site influenza vaccination strategy in Italian healthcare workers: a systematic review and statistical analysis[J]. Expert Rev Vaccines, 2023, 22(1): 17-24. PMID: 36409195. DOI: 10.1080/14760584.2023.2149500.
Fodor E, Nagy RN, Nógrádi A, et al. An observational study on the pharmacokinetics of oseltamivir in lactating influenza patients[J]. Clin Pharmacol Ther, 2024, 115(2): 318-323. PMID: 37975276. DOI: 10.1002/cpt.3107.
17 National Institute of Child Health and Human Development. Drugs and lactation database (LactMed?)[EB/OL]. [2024-02-15]. https://www.ncbi.nlm.nih.gov/books/NBK501922/.
18 Centers for Disease Control and Prevention. Considerations regarding 2009 H1N1 in intrapartum and postpartum hospital settings[EB/OL]. [2022-04-11]. https://portal.ilca.org/files/in_the_news/Webinars2009/H1N1_December_1_Webinar.pdf.
Butler J, Gunnarsson R, Traves A, et al. Severe respiratory syncytial virus infection in hospitalized children less than 3 years of age in a temperate and tropical climate[J]. Pediatr Infect Dis J, 2019, 38(1): 6-11. PMID: 30531526. DOI: 10.1097/INF.0000000000002026.
Kampmann B, Madhi SA, Munjal I, et al. Bivalent prefusion F vaccine in pregnancy to prevent RSV illness in infants[J]. N Engl J Med, 2023, 388(16): 1451-1464. PMID: 37018474. DOI: 10.1056/NEJMoa2216480.
American Academy of Pediatrics Committee on Infectious Diseases, American Academy of Pediatrics Bronchiolitis Guidelines Committee. Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection[J]. Pediatrics, 2014, 134(2): e620-e638. PMID: 25070304. DOI: 10.1542/peds.2014-1666.
Griffin MP, Yuan Y, Takas T. Single-dose nirsevimab for prevention of RSV in preterm infants[J]. N Engl J Med, 2020, 383(5): 415-425. PMID: 32726528. DOI: 10.1056/NEJMoa1913556.
Robbie GJ, Criste R, Dall'acqua WF, et al. A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults[J]. Antimicrob Agents Chemother, 2013, 57(12): 6147-6153. PMID: 24080653. PMCID: PMC3837853. DOI: 10.1128/AAC.01285-13.
Hammitt LL, Dagan R, Yuan Y, et al. Nirsevimab for prevention of RSV in healthy late-preterm and term infants[J]. N Engl J Med, 2022, 386(9): 837-846. PMID: 35235726. DOI: 10.1056/NEJMoa2110275.
Domachowske J, Madhi SA, Sim?es EAF, et al. Safety of nirsevimab for RSV in infants with heart or lung disease or prematurity[J]. N Engl J Med, 2022, 386(9): 892-894. PMID: 35235733. DOI: 10.1056/NEJMc2112186.
Jones JM, Fleming-Dutra KE, Prill MM, et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the Advisory Committee on Immunization Practices: United States, 2023[J]. MMWR Morb Mortal Wkly Rep, 2023, 72(34): 920-925. PMID: 37616235. PMCID: PMC10468217. DOI: 10.15585/mmwr.mm7234a4.
Sim?es EAF, Madhi SA, Muller WJ, et al. Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials[J]. Lancet Child Adolesc Health, 2023, 7(3): 180-189. PMID: 36634694. PMCID: PMC9940918. DOI: 10.1016/S2352-4642(22)00321-2.
Zhu Q, McLellan JS, Kallewaard NL, et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants[J]. Sci Transl Med, 2017, 9(388): eaaj1928. PMID: 28469033. DOI: 10.1126/scitranslmed.aaj1928.
Yung CF, Kam KQ, Wong MSY, et al. Environment and personal protective equipment tests for SARS-CoV-2 in the isolation room of an infant with infection[J]. Ann Intern Med, 2020, 173(3): 240-242. PMID: 32236490. PMCID: PMC7133054. DOI: 10.7326/M20-0942.
Yeo KT, Biswas A, Ying Ho SK, et al. Guidance for the clinical management of infants born to mothers with suspected/confirmed COVID-19 in Singapore[J]. Singapore Med J, 2022, 63(9): 489-496. PMID: 33866749. PMCID: PMC9678132. DOI: 10.11622/smedj.2021045.
Harada YU, Amo H, Ono T, et al. Inactivation of SARS-CoV-2 by commercially available disinfectants and cleaners[J]. Biocontrol Sci, 2022, 27(4): 223-228. PMID: 36567119. DOI: 10.4265/bio.27.223.
SHI Li-Xiu, FENG Jin-Xing, WEI Yan-Fang, LU Xin-Ru, ZHANG Yu-Xi, YANG Lin-Ying, HE Sheng-Nan, CHEN Pei-Juan, HAN Jing, CHEN Cheng, TU Hui-Ying, YU Zhang-Bin, HUANG Jin-Jie, ZENG Shu-Juan, CHEN Wan-Ling, LIU Ying, GUO Yan-Ping, MAO Jiao-Yu, LI Xiao-Dong, ZHANG Qian-Shen, XIE Zhi-Li, HUANG Mei-Ying, YAN Kun-Shan, YING Er-Ya, CHEN Jun, WANG Yan-Rong, LIU Ya-Ping, SONG Bo, LIU Hua-Yan, XIAO Xiao-Dong, TANG Hong, WANG Yu-Na, CAI Yin-Sha, LONG Qi, XU Han-Qiang, WANG Hui-Zhan, SUN Qian, HAN Fang, ZHANG Rui-Biao, YANG Chuan-Zhong, DOU Lei, SHI Hui-Ju, WANG Rui, JIANG Ping. A multicenter study of neonatal stroke in Shenzhen, China[J]. CJCP, 2024, 26(5): 450-455.